Medical Affairs (MA) is a “sleeping giant” with potential to offer companies significant strategic value. While MA has occasionally been siloed – for instance, Commercial driving conversations, consultation occurring late in the process, MA not being credited for value creation during launch prep, etc. – there is positive momentum. MA’s future is evolving in healthcare innovation and leadership, by being incorporated into the development of cross-functional goals to help achieve patient benefits, playing a leading role in driving value outcomes, HEOR, etc. MA is also growing its capabilities and expertise in digitalization and communication, both externally and internally. At the same time, there are mixed perceptions about MA’s role going forward, including concerns that MA is hiding behind Compliance or shying away from measuring impact through the better use of KPIs. Are there capabilities and responsibilities MA needs to embrace to drive and deliver a high-performing organization, and what are the risks in this transition?
- Discuss the current and future role of Medical Affairs in overall pharmaceutical strategic decision making
- Characterize value that Medical Affairs does and could provide
- Highlight potential ways in which Medical Affairs could evolve in the future
- Discuss key questions that may shape MA perceptions and activities going forward